Cargando…
Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19
BACKGROUND: Severe cases of coronavirus disease 2019 (COVID-19) are characterized by progressive respiratory failure and the development of acute respiratory distress syndrome (ARDS), with high mortality rates for patients requiring mechanical ventilation. Levels of the vascular growth factor Angiop...
Autores principales: | Jones, Rosie S., Smith, Patricia S., Berg, Paul H., de la Peña, Amparo, Cook, Paul P., Shawa, Imad, Kioussopoulos, Kathleen M., Hu, Yu, Schott, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382233/ https://www.ncbi.nlm.nih.gov/pubmed/35991210 http://dx.doi.org/10.1177/11795484221119316 |
Ejemplares similares
-
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
por: Martin-Liberal, Juan, et al.
Publicado: (2020) -
A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
por: Downing, AnnCatherine M, et al.
Publicado: (2014) -
CT features of confirmed and presumed gastric wall edema in dogs
por: Murakami, Masahiro, et al.
Publicado: (2022) -
Visual loss and presumed pseudoxanthoma elasticum confirmed with genetic analysis but not with skin examination and biopsies
por: Aerts, Carolien, et al.
Publicado: (2011) -
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
por: Chen, Peter, et al.
Publicado: (2020)